PharmTech Drug Digest 11.20
News|Articles|March 18, 2016

Gyros AB and Protein Technologies Merge to Form Gyros Protein Technologies AB

The merger creates a provider of sample prep, synthesis, and bioanalytical tools for biotherapeutics discovery, development, and manufacturing.

The merger creates a provider of sample prep, synthesis, and bioanalytical tools for biotherapeutics discovery, development, and manufacturing.

Gyros AB and Protein Technologies announced on March 16, 2016 that the companies have entered into a definitive merger agreement to form Gyros Protein Technologies AB. The merger is expected to be complete by mid-April 2016 and is subject to certain closing conditions.

Gyros Protein Technologies combines Gyros’ microfluidics, systems development, and immunoassay knowledge with Protein Technologies’ insight in developing and manufacturing instruments for peptide synthesis. The new company will provide a range of sample prep, synthesis, and bioanalytical tools for biotherapeutics discovery, development, and bioprocessing. According to a press announcement from the company, Gyros Protein Technologies will be led by Dan Calvo as CEO (currently CEO of Gyros AB) and Erik Wiberg as CFO (currently CFO of Protein Technologies).

Source: Gyros AB


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.